AstraZeneca has recently launched a new health-tech business called Evinova, which will leverage the company’s expertise in clinical trial design and study delivery. The Anglo-Swedish pharmaceutical giant aims to provide solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.
Evinova’s offerings include advanced data collection methods and machine learning algorithms to support teams in designing their studies. The goal is to speed up the development of new medicines, bring care closer to home for patients, and reduce the strain on healthcare systems. The company has announced major partnerships with clinical research organizations Parexel and Fortrea to expand the reach of Evinova’s digital health solutions to a broader customer base.
AstraZeneca’s CEO, Pascal Soriot, is confident that Evinova can have a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company expects the digital health market to grow significantly in the coming years, projecting it to be worth more than $900 billion by 2032.
For more information about Evinova and its offerings, please contact Michael Susin at michael.susin@wsj.com.